


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Compounds of the formula I



in which

- D denotes an aromatic five-membered heterocyclic ring having 1 to 4 N, O and/or S atoms which is unsubstituted or mono- or polysubstituted by Hal, A, OR², N(R²)₂, NO₂, CN, COOR² or CON(R²)₂,
- X denotes NR³ or O,
- R¹ denotes H, Ar, Het, cycloalkyl or A, which may be substituted by OR², SR², N(R²)₂, Ar, Het, cycloalkyl, CN, COOR² or CON(R²)₂,
- R² denotes H, A, -[C(R³)₂]_n-Ar, -[C(R³)₂]_n-Het, -[C(R³)₂]_n-cycloalkyl, -[C(R³)₂]_n-N(R³)₂ or -[C(R³)₂]_n-OR³,
- R³ denotes H or A,
- W denotes -[C(R³)₂]_n-,
- Y denotes alkylene, cycloalkylene, Het-diyl or Ar-diyl,
- T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocyclic ring having 0 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, -[C(R³)₂]_n-Ar, -[C(R³)₂]_n-Het, -[C(R³)₂]_n-cycloalkyl, OR³, N(R³)₂, NO₂, CN, COOR², CON(R²)₂, NR²COA, NR²CON(R²)₂, NR²SO₂A, COR², SO₂NR² and/or S(O)_mA and/or carbonyl oxygen, or N(R²)₂ and, if Y = piperidine-1,4-diyl, also R² or cycloalkyl,
- A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH₂ groups may be replaced by O or S atoms and/or by

- CH=CH- groups and/or also 1-7 H atoms may be replaced by F,
- Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂N(R³)₂, S(O)_mA, -[C(R³)₂]_n-COOR^{2'} or -O-[C(R³)₂]_o-COOR^{2'},
- R^{2'} denotes H, A, -[C(R³)₂]_n-Ar', -[C(R³)₂]_n-Het', -[C(R³)₂]_n-cycloalkyl, -[C(R³)₂]_n-N(R³)₂ or -[C(R³)₂]_n-OR³,
- R^{2''} denotes H, A, -[C(R³)₂]_n-Ar' or -[C(R³)₂]_n-cycloalkyl, -[C(R³)₂]_n-N(R³)₂ or -[C(R³)₂]_n-OR³,
- Ar' denotes phenyl or benzyl, each of which is unsubstituted or mono- or disubstituted by Hal or A,
- Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, =S, =N(R³)₂, Hal, A, -[C(R³)₂]_n-Ar, -[C(R³)₂]_n-Het¹, -[C(R³)₂]_n-cycloalkyl, -[C(R³)₂]_n-OR^{2'}, -[C(R³)₂]_n-N(R^{2'})₂, NO₂, CN, -[C(R³)₂]_n-COOR^{2'}, -[C(R³)₂]_n-CON(R^{2'})₂, -[C(R³)₂]_n-NR^{2'}COA, NR^{2'}CON(R^{2'})₂, -[C(R³)₂]_n-NR^{2'}SO₂A, COR^{2'}, SO₂NR^{2'} and/or S(O)_mA,
- Het¹ denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 2 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen, =S, =N(R³)₂, Hal, A, OR^{2''}, N(R^{2''})₂, NO₂, CN, COOR^{2''}, CON(R^{2''})₂, NR^{2''}COA, NR^{2''}CON(R^{2''})₂, NR^{2''}SO₂A, COR^{2''}, SO₂NR^{2''} and/or S(O)_mA,
- Hal denotes F, Cl, Br or I,
- n denotes 0, 1 or 2,
- m denotes 0, 1 or 2,
- o denotes 1, 2 or 3,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

2. (Original) Compounds according to Claim 1,
in which
D denotes an aromatic five-membered heterocyclic ring having 1 to 2 N,
O and/or S atoms which is unsubstituted or mono- or disubstituted by
Hal,
and pharmaceutically usable derivatives, solvates and stereoisomers thereof,
including mixtures thereof in all ratios.
3. (Currently Amended) Compounds according to Claim 1 ~~or 2~~,
in which
D denotes a thienyl ring which is mono- or disubstituted by Hal,
and pharmaceutically usable derivatives, solvates and stereoisomers thereof,
including mixtures thereof in all ratios.
4. (Currently Amended) Compounds according to ~~one or more of Claims 1-3~~
Claim 1, in which
R² denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,
and pharmaceutically usable derivatives, solvates and stereoisomers thereof,
including mixtures thereof in all ratios.
5. (Currently Amended) Compounds according to ~~one or more of Claims 1-4~~
Claim 1, in which
R¹ denotes H or unsubstituted phenyl, thienyl or alkyl having 1-6 C
atoms,
and pharmaceutically usable derivatives, solvates and stereoisomers thereof,
including mixtures thereof in all ratios.
6. (Currently Amended) Compounds according to ~~one or more of Claims 1-5~~
Claim 1, in which
X denotes NH or O,
and pharmaceutically usable derivatives, solvates and stereoisomers thereof,
including mixtures thereof in all ratios.

7. (Currently Amended) Compounds according to ~~one or more of Claims 1-6~~
Claim 1, in which
W denotes $(CH_2)_n$,
and pharmaceutically usable derivatives, solvates and stereoisomers thereof,
including mixtures thereof in all ratios.
8. (Currently Amended) Compounds according to ~~one or more of Claims 1-7~~
Claim 1, in which
Y denotes Ar-diyl or Het-diyl,
and pharmaceutically usable derivatives, solvates and stereoisomers thereof,
including mixtures thereof in all ratios.
9. (Currently Amended) Compounds according to ~~one or more of Claims 1-8~~
Claim 1, in which
T denotes a mono- or bicyclic saturated, unsaturated or aromatic
heterocyclic ring having 1 to 2 N and/or O atoms, which may be
unsubstituted or mono- or disubstituted by carbonyl oxygen,
or $N(R^2)_2$
and, if Y = piperidine-1,4-diyl, also R^2 ,
and pharmaceutically usable derivatives, solvates and stereoisomers thereof,
including mixtures thereof in all ratios.
10. (Currently Amended) Compounds according to ~~one or more of Claims 1-9~~
Claim 1, in which
T denotes a mono- or bicyclic saturated or unsaturated heterocyclic ring
having 1 to 2 N and/or O atoms which is mono- or disubstituted by
carbonyl oxygen ($=O$),
or $N(R^2)_2$
and, if Y = piperidine-1,4-diyl, also R^2 ,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

11. (Currently Amended) Compounds according to ~~one or more of Claims 1-10~~
Claim 1, in which

T denotes piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, each of which is mono- or disubstituted by carbonyl oxygen,
or N(R²)₂
and, if Y = piperidine-1,4-diyl, also R²,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

12. (Currently Amended) Compounds according to ~~one or more of Claims 1-11~~
Claim 1, in which

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by
Hal, A, OA, SO₂A, COOR², SO₂NH₂ or CN,
and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

13. (Currently Amended) Compounds according to ~~one or more of Claims 1-12~~
Claim 1, in which

D denotes an aromatic five-membered heterocyclic ring having 1 to 2 N,
O and/or S atoms which is unsubstituted or mono- or disubstituted by
Hal,

R¹ denotes H or unsubstituted phenyl, thienyl or alkyl having 1-6 C
atoms,

R² denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

X denotes NH or O,

W denotes W (CH₂)_n,

Y denotes Ar-diyl, pyridinediyl or piperidinediyl,
 Ar denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO₂A, COOR², SO₂NH₂ or CN,
 T denotes piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, each of which is mono- or disubstituted by carbonyl oxygen, or N(R²)₂
 and, if Y = piperidine-1,4-diyl, also R²,
 and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

14. (Currently Amended) Compounds according to ~~one or more of Claims 1-13~~
Claim 1, in which

D denotes thienyl, thiazolyl or furyl, each of which is mono- or disubstituted by Hal,
 R¹ denotes H or unsubstituted phenyl, thienyl or alkyl having 1-6 C atoms,
 R² denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,
 X denotes NH or O,
 W denotes W (CH₂)_n,
 Y denotes Ar-diyl, pyridinediyl or piperidinediyl,
 Ar denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO₂A, COOR², SO₂NH₂ or CN,
 T denotes piperidin-1-yl, pyrrolidin-1-yl, pyridinyl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazinyl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, each of which is unsubstituted or mono- or disubstituted by carbonyl oxygen, or N(R²)₂
 and, if Y = piperidine-1,4-diyl, also R²,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

15. (Original) Compounds according to Claim 1 selected from the group

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]valeramide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-3-methylphenyl]valeramide,

2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]acetamide,

(R)-2-[3-(5-bromothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]valeramide,

(R)-2-[3-(5-bromofuran-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]valeramide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]-2-phenylacetamide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]-2-(thiophen-2-yl)acetamide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(2-oxopiperidin-1-yl)-phenyl]valeramide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(2-oxo-1*H*-pyrazin-1-yl)-phenyl]valeramide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[2-oxo-3,4,5,6-tetrahydro-[1,2']bipyridinyl-5'-yl]valeramide,

(S)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]-2-phenylacetamide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenylmethyl]valeramide,

(R)-2-[3-(5-chlorothiazol-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]valeramide,

(R)-2-[N-(5-chlorothiophen-2-yl)carbamoyloxy]-N-[[4-(3-oxo-morpholin-4-yl)phenyl]valeramide,

(R)-2-[N-(5-chlorothiophen-2-yl)carbamoyloxy]-N-[C-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)methyl]valeramide,


(R)-2-[N-(5-chlorothiophen-2-yl)carbamoyloxy]-N-[1-isopropyl-piperidin-4-ylmethyl]-2-phenylacetamide,

(R)-2-[N-(5-chlorothiophen-2-yl)carbamoyloxy]-N-[[4-(morpholin-4-yl)-phenyl]valeramide

(R)-2-[N-(5-chlorothiophen-2-yl)carbamoyloxy]-N-(4-dimethylamino-phenyl)-2-phenylacetamide

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

16. (Currently Amended) Process for the preparation of compounds of the formula I according to ~~Claims 1-15~~ Claim 1 and pharmaceutically usable derivatives, solvates and stereoisomers thereof, characterised in that
- a) a compound of the formula II



in which

R¹, W, X, Y and T have the meaning indicated in Claim 1,

is reacted with a compound of the formula III



in which

D has the meaning indicated in Claim 1,


or

b) a compound of the formula IV



in which W, Y and T have the meaning indicated in Claim 1,

is reacted with a compound of the formula V



in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group, and

R¹, X and D have the meanings indicated in Claim 1,

and/or

a base or acid of the formula I is converted into one of its salts.

17. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 15~~ Claim 1 as inhibitors of coagulation factor Xa.
18. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 15~~ Claim 1 as inhibitors of coagulation factor VIIa.
19. (Currently Amended) Medicaments comprising at least one compound of the formula I according to ~~one or more of Claims 1 to 15~~ Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including

mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

20. (Currently Amended) Medicaments comprising at least one compound of the formula I according to ~~one or more of Claims 1 to 15~~ Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
21. (Currently Amended) Use of compounds according to ~~one or more of Claims 1 to 15~~ Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases.
22. (Currently Amended) Set (kit) consisting of separate packs of
 - (a) an effective amount of a compound of the formula I according to ~~one or more of Claims 1 to 15~~ Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and
 - (b) an effective amount of a further medicament active ingredient.
23. (Currently Amended) Use of compounds of the formula I according to ~~one or more of Claims 1 to 15~~ Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, in combination with at least one further medicament active ingredient.